Clinical Scenario

This protocol applies to patients presenting with symptomatic loiasis whose microfilarial load is confirmed to be below 8,000 microfilariae per mL of blood. At this load level, available data indicate that the risk of serious treatment-related complications approaches zero, supporting active antifilarial treatment.

Treatment Approach (Partial Overview)

The drug of choice for this scenario is an oral antiparasitic agent — diethylcarbamazine (DEC). Supportive measures targeting early treatment-related effects such as Calabar swelling or pruritus may also be incorporated. The full dosing schedule, course duration, and complete management algorithm are available in the structured protocol.

References

Symptomatic loiasis with MF/mL <8,000.
Available data demonstrate that the risk of fatal encephalopathy in patients treated with DEC with microfilarial loads <8,000 microfilariae per mL approaches zero.
The drug of choice for the treatment of loiasis is diethylcarbamazine (DEC).
Some authors suggest that these symptoms might be attenuated with the concomitant use of antihistamines or corticosteroids during the first seven days of treatment.
Most patients will achieve cure, defined as resolution of symptoms, resolution of eosinophilia, and decreasing antifilarial antibody titers, with one or two courses of DEC.

View source ↗

Treatment of Symptomatic Loiasis with Microfilarial Load Below 8,000 Microfilariae per mL of Blood

Clinical Scenario

Treatment Approach (Partial Overview)

Treatment Goals

References